Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...

Shionogi & Co (($JP:4507)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Shionogi & Co.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

The European Commission (EC) has authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus ...

European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...

London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...